Mechanisms underlying early development of pulmonary vascular obstructive disease in Down syndrome: An imbalance in biosynthesis of thromboxane A 2 and prostacyclin

American Journal of Medical Genetics, Part A

Volumn 152, Issue 8, 2010, Pages 1919-1924

  Fukushima, Hiroyuki ^a   Kosaki, Kenjiro ^a   Sato, Reiko ^a   Yagihashi, Tatsuhiko ^a   Gatayama, Ryohei ^a   Kodo, Kazuki ^a   Hayashi, Takuya ^a   Nakazawa, Maki ^a   Tsuchihashi, Takatoshi ^a   Maeda, Jun ^a   Kojima, Yoshifumi ^a   Yamagishi, Hiroyuki ^a   Takahashi, Takao ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Down syndrome; Prostacyclin; Pulmonary hypertension; Thromboxane A2

Indexed keywords

11 OXOTHROMBOXANE B2; 2,3 DINOR 6 OXOPROSTAGLANDIN F1 ALPHA; ICOSANOID; PROSTACYCLIN; THROMBOXANE A2;

ARTICLE; CHILD; CLINICAL ARTICLE; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DOWN SYNDROME; FEMALE; HEART LEFT RIGHT SHUNT; HUMAN; INFANT; MALE; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEIN URINE LEVEL; PULMONARY HYPERTENSION; PULMONARY VASCULAR OBSTRUCTIVE DISEASE; URINARY EXCRETION; VASOCONSTRICTION;

6-KETOPROSTAGLANDIN F1 ALPHA; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DOWN SYNDROME; EPOPROSTENOL; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; INFANT; LUNG DISEASES, OBSTRUCTIVE; MALE; PROGNOSIS; PULMONARY HEART DISEASE; RADIOIMMUNOASSAY; THROMBOXANE A2; THROMBOXANE B2;

EID: 77955296599     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.33555     Document Type: Article

References (34)

1. 2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. Circulation 88: 2117-2122.
2. Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, McLaughlin VV, American College of Chest Physicians. 2004. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126:35S-62S.
3. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. 2007. Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice guidelines. Chest 131:1917-1928.
4. Chi TPL, Krovetz J. 1975. The pulmonary vascular bed in children with Down syndrome. J Pediatr 86:533-538.
5. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE. 1992. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327:70-75.
6. Clapp S, Perry BL, Farooki ZQ, Jackson WL, Karpawich PP, Hakimi L, Arciniegas E, Green EW, Pinski WW. 1990. Down's syndrome, complete atrioventricular canal, and pulmonary vascular obstructive disease. J Thorac Cardiovasc Surg 100:115-121.
7. Cooney TP, Thurlbeck WM. 1982. Pulmonary hypoplasia in Down's syndrome. N Engl J Med 307:1170-1173.
8. De La Torre R, Casado A, López-Fernández E, Carrascosa D, Ramírez V, Sáez J. 1996. Overexpression of copper-zinc superoxide dismutase in trisomy 21. Experientia 52:871-873.
9. Doroudi R, Gan L, Sjögren S, Jern S. 2000. Effects of shear stress on eicosanoid gene expression and metabolite production in vascular endothelium as studied in a novel biochemical perfusion model. Biochem Biophys Res Commun 269:257-264.
10. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE. 1998. Cyclooxygenase in biology and disease. FASEB J 12:1063-1073.
11. Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, Olschewski H, Peacock A, Pietra G, Rubin LJ, Simonneau G, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, McGregor K, Morais J, Oto A, Smiseth OA, Barbera JA, Gibbs S, Hoeper M, Humbert M, Naeije R, Pepke-Zaba J. 2004. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The task force on diagnosis and treatment of pulmonary hypertension of European society of cardiology. Eur Heart J 25: 2243-2278.
12. Hamberg M, Svensson J, Samuelsson B. 1975. Thromboxanes:Anew group of biologically active compounds derived from prostaglandin endoper-oxides. Proc Natl Acad Sci USA 72:2994-2998.
13. Hiramatsu M, Hayashi Y, Yamamoto S, Hayashi A, Sawada M, Hamanaka N, Yamashita K. 1994. Application of an alpha-sidechain length-specific monoclonal antibody to immunoaffinity purification and enzyme immunoassay of 2,3-dinor-6-keto-prostaglandin F1 alpha from human urine. Prostaglandins Leukot Essent Fatty Ascids 50:69-79.
14. Humbert M, Sitbon O, Simonneau G. 2004. Treatment of pulmonary arterial hypertension. N Engl J Med 351:1425-1436.
15. 2 synthesis. Eur J Pharmacol 107: 259-262.
16. Leonhardt A, Busch C, Schweer H, Seyberth HW. 1992. Reference intervals and developmental changes in urinary prostanoid excretion in healthy newborns, infants and children. Acta Paediatr 81:191-196.
17. Loughlin GM, Wynne JW, Victorica BE. 1981. Sleep apnea as a possible cause of pulmonary hypertension in Down syndrome. J Pediatr 98:435-437.
18. McLaughlin VV, Archer SL, Bedesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J. 2009. ACCF/AHA 2009 expert consensus document on pulmonary hypertension:Areport of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association. Circulation 119:2250-2294.
19. Moncada S, Gryglewski R, Bunting S, Vane JR. 1976. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263:663-665.
20. Pakala R, Willerson JT, Benedict CR. 1997. Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation 96:2280-2286. (Pubitemid 27425834)
21. Pastor MC, Sierra C, Doladé M, Navarro E, Brandi N, Cabré E, Mira A, Serés A. 1998. Antioxidant enzymes and fatty acid status in erythrocytes of Down syndrome patients. Clin Chem 44:924-929.
22. Pastore A, Tozzi G, Gaeta LM, Giannotti A, Bertini E, Federici G, Digilio MC, Piemonte F. 2003. Glutathione metabolism and antioxidant enzymes in children with Down syndrome. J Pediatr 142:583-585.
23. Perneby C, Granström E, Beck O, Fitzgerald D, Harhen B, Hjemdahl P. 1999. Optimization of an enzyme immunoassay for 11-dehydro-thromboxane B(2) in urine: Comparison with GC-MS. Thromb Res 96:427-436.
24. Sachinidis A, Flesch M, Ko Y, Schrör K, Böhm M, Düsing R, Vetter H. 1995. Thromboxane A2 and vascular smooth muscle cell proliferation. Hypertension 26:771-780.
25. Shah PS, Hellmann J, Adatia I. 2004. Clinical characteristics and follow up of Down syndrome infants without congenital heart disease who presented with persistent pulmonary hypertension of newborn. J Perinat Med 32:168-170.
26. Sheskin DJ. 2004. Inferential statistical test employed with factorial design. In: Sheskin DJ, editor. Handbook of parametric and nonparametric statistical procedures, 3rd edition. Boca Raton: Chapman & Hall/CRC. pp. 885-942.
27. Sinzinger H, Zidek T, Fitscha P, O'Grady J, Wangner O, Kaliman J. 1987. Prostaglandin I2 reduces activation of human arterial smooth muscle cells in-vivo. Prostaglandins 33:915-918.
28. Smith WL, Garavito RM, DeWitt DL. 1996. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271:33157-33160.
29. Suzuki K, Yamaki S, Mimori S, Murakami Y, Mori K, Takahashi Y, Kikuchi T. 2000. Pulmonary vascular disease in Down's syndrome with complete atrioventricular septal defect. Am J Cardiol 86:434-437.
30. Ullrich V, Zou MH, Bachschmid M. 2001. New physiological and pathophysiological aspects on the thromboxane A2-prostacyclin regulatory system. Biochim Biophys Acta 1532:1-14.
31. Wharton J, Davie N, Upton PD, Yacoub MH, Polak JM, Morrell NW. 2000. Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation 102:3130-3136.
32. Yamaki S, Horiuchi T, Sekino Y. 1983. Quantitative analysis of pulmonary vascular disease in simple cardiac anomalies with the Down syndrome. Am J Cardiol 51:1502-1506.
33. Zou MH, Ullrich V. 1996. Peroxynitrite formed by simultaneous generation of nitric oxide and superoxide selectively inhibits bovine aortic prostacyclin synthase. FEBS Lett 382:101-104.
34. Zou M, Martin C, Ullrich V. 1997. Tyrosine nitration as a mechanism of selective inactivation of prostacyclin synthase by peroxynitrite. Biol Chem 378:707-713.